Otsuka/Lundbeck Closer To Adding Alzheimer’s Agitation To Rexulti Label
Executive Summary
With no currently approved treatment for agitation in Alzheimer’s disease, analysts see a solid revenue opportunity for Rexulti. The companies plan to file a supplemental NDA later this year.
You may also be interested in...
Otsuka, Lundbeck Seek Alzheimer's Agitation Claim For Antipsychotic
Otsuka and Lundbeck are seeking to expand the use of psychiatry drug Rexulti into Alzheimer's agitation to up the product's commercial prospects, but mixed Phase III data for the drug mean a third regulatory nod is uncertain.
Lundbeck's Alzheimer's Strategy Targets Symptoms And Disease Modification
The private company may be behind the leaders, but with a long-term plan and a strategy of coming in with complementary therapies like the 5-HT6 receptor antagonist idalopirdine and the dopamine antagonist Rexulti (brexpiprazole), it could be a stable player in Alzheimer's.
FDA approves Otsuka/Lundbeck atypical antipsychotic Rexulti
The FDA late on 10 July approved Otsuka's and Lundbeck's new drug application (NDA) to market Rexulti (brexpiprazole), an atypical antipsychotic, as adjunctive treatment for adults with major depressive disorder (MDD), which affects about 15 million adults in the US, and as a treatment for adults with schizophrenia, which affects about 2.4 million American adults.